We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+17.33%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$961M
AUM Growth
+$374M
Cap. Flow
+$41.2M
Cap. Flow %
4.29%
Top 10 Hldgs %
44.93%
Holding
194
New
69
Increased
29
Reduced
39
Closed
48

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$24.6M
2
AGN
Allergan plc
AGN
+$24.2M
3
MRK icon
Merck
MRK
+$22.3M
4
AMGN icon
Amgen
AMGN
+$17.6M
5
ENDP
Endo International plc
ENDP
+$17.6M

Top Sells

Rank Stock Value
1
NVS icon
Novartis
NVS
+$33.6M
2
SHPG
Shire pic
SHPG
+$20.7M
3
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$18.2M
4
BIIB icon
Biogen
BIIB
+$11.8M
5
ISRL
Isramco Inc
ISRL
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 59.2%
2 Miscellaneous 33.43%
3 Technology 2.61%
4 Industrials 1.8%
5 Consumer Discretionary 1.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASMB icon
126
Assembly Biosciences
ASMB
$516M
$1.32M 0.14%
+8,333
New +$1.13M
EXEL icon
127
Exelixis
EXEL
$14.5B
$1.28M 0.13%
+500,000
New +$1.16M
ASND icon
128
Ascendis Pharma A/S
ASND
$15.7B
$1.22M 0.13%
+70,000
New +$1.27M
ALDX icon
129
Aldeyra Therapeutics
ALDX
$83.3M
$1.19M 0.12%
+115,000
New +$1.17M
STML
130
DELISTED
Stemline Therapeutics, Inc.
STML
$1.17M 0.12%
+80,957
New +$1.24M
HRTX icon
131
Heron Therapeutics
HRTX
$59.9M
$1.16M 0.12%
+79,900
New +$901K
SGNT
132
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$1.16M 0.12%
+50,000
New +$1.32M
IMMU
133
DELISTED
Immunomedics Inc
IMMU
$1.15M 0.12%
+300,000
New +$1.3M
CBAY
134
DELISTED
Cymabay Therapeutics
CBAY
$1.09M 0.11%
157,179
-233,176
-60% -$2.24M
PTN
135
Palatin Technologies
PTN
$18.6M
$1.06M 0.11%
832
– –
CYTO
136
DELISTED
Altamira Therapeutics Ltd
CYTO
$997K 0.1%
+2
New +$806K
JUNO
137
DELISTED
Juno Therapeutics, Inc.
JUNO
$910K 0.09%
15,000
– –
CARM
138
DELISTED
Carisma Therapeutics
CARM
$777K 0.08%
4,356
– –
SVRA icon
139
Savara
SVRA
$1.11B
$667K 0.07%
19,641
– –
ACHN
140
DELISTED
Achillion Pharmaceuticals
ACHN
$646K 0.07%
65,538
-60,000
-48% -$749K
NBSE
141
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$476K 0.05%
+469
New +$1.55M
SPNS
142
DELISTED
Sapiens International
SPNS
$463K 0.05%
+56,420
New +$417K
BLRX
143
BioLineRX
BLRX
$12.3M
$408K 0.04%
+322
New +$396K
SPPI
144
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$304K 0.03%
+50,000
New +$333K
ARCT icon
145
Arcturus Therapeutics
ARCT
$481M
$1K ﹤0.01%
29
-5,471
-99% -$241K
ARDX icon
146
Ardelyx
ARDX
$873M
– –
-32,700
Closed -$618K
ARWR icon
147
Arrowhead Research
ARWR
$9.57B
– –
-400,000
Closed -$2.95M
BHC icon
148
CALL
Bausch Health
BHC
$2.11B
– –
-97,200
Closed -$1.4M
CSX icon
149
CSX Corp
CSX
$88.7B
– –
-178,944
Closed -$2.16M
CYTK icon
150
Cytokinetics
CYTK
$9.72B
– –
-493,212
Closed -$3.95M
4 5
6
7 8

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q1 2015 Portfolio in Review

As of Q1 2015, Sphera Funds Management held 194 positions worth $961M, up 64% from $587M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management deployed $41.2M of net new capital in Q1 2015, opening 69 new positions and adding to 29 existing holdings. Its largest new stake was AbbVie: 407,000 shares worth $23.8M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 69% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the largest reduction was Novartis, an estimated $33.6M trimmed.

  • Sphera Funds Management's largest Q1 2015 buy was AbbVie: 407,000 shares worth $23.8M.
  • Sphera Funds Management added most to Allergan plc in Q1 2015, an estimated $24.2M increase.
  • Sphera Funds Management's biggest Q1 2015 reduction was Novartis, cutting an estimated $33.6M.
  • Sphera Funds Management fully exited SALIX PHARMACEUTICALS LTD DEL in Q1 2015, selling an estimated $18.2M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $961M portfolio in Q1 2015.
  • Sphera Funds Management opened 69 new positions and closed 48 in Q1 2015.
  • Sphera Funds Management's portfolio value rose 64% quarter-over-quarter to $961M.

Based on Sphera Funds Management's 13F filing for Q1 2015, filed 11 May 2015.